Organon & Co.
NYSE:OGNDrug Manufacturers - General
+$0.01 today
- Market cap
- $3.66B
- Beta
- 1.54
- P/E (TTM)
- 14.2
- EPS (TTM)
- $0.94
- Dividend yield
- 0.60%
Volume 3.90M
Average 8.57M
OGN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Organon & Co.NYSE: OGN
Net Income · Q3 FY2026 · quarter ended Sep 2026
Net income growth accelerates
Q3 FY2026 net income of $164M rose 2.5% year over year, ahead of the -108.1% change in trailing-twelve-month net income. Over 3 fiscal years it compounded at -41.1% a year.
Context
- Net income amounted to 3.0% of revenue in FY2025, down 10.5 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of $874.85M (+367.8%) for the fiscal year ending Dec 2026, a step up from the -78.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $164M+212.5% QoQ
- Last fiscal yearDec 2025
- $187M-78.4% YoY
- LTMSep 2026
- -$40.75M-108.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 187M USD
- Year-over-year change
- -78.4%
- 4-year CAGR
- -39.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 187M | -78.4% |
| FY2024 | 2024-12-31 | 864M | -15.5% |
| FY2023 | 2023-12-31 | 1.02B | +11.6% |
| FY2022 | 2022-12-31 | 917M | -32.1% |
| FY2021 | 2021-12-31 | 1.35B | — |
Net Income vs competitors
How OGN compares with its peers on the latest reported figures
- OGN's LTM Sep 2026 net income of $40.75M is the smallest of the 10 companies compared; the peer median is $112.24M.
- Its year-over-year change of -108.1% is the 9th highest of 10, against a peer median of +35.0%.
- Net income amounts to 0.7% of revenue for OGN, versus a peer median of 14.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Feb 2026 | $1.83B | +35.0% | +70.9% | 154.9% | |
| LTM Jun 2026 | $314.11M | +418.0% | — | 100.8% | |
| LTM Mar 2026 | $196.34M | -22.8% | -9.6% | 3.6% | |
| LTM Jun 2026 | $181.27M | +0.2% | -4.4% | 18.9% | |
| LTM Sep 2026 | $150.09M | -7.5% | +38.3% | 7.7% | |
| LTM Jun 2026 | $112.24M | +155.3% | +25.2% | 66.1% | |
| LTM Mar 2026 | $95.23M | +199.6% | -0.6% | 6.3% | |
| LTM Mar 2026 | $80.73M | -183.6% | — | 14.4% | |
GRDNGuardian Pharmacy Services, Inc. | LTM Jun 2026 | $66.52M | +187.8% | -0.3% | 4.5% |
| LTM Sep 2026 | $40.75M | -108.1% | -41.1% | 0.7% | |
| Peer median (excluding OGN) | $112.24M | +35.0% | -0.3% | 14.4% | |
Competitors are the stored peer set for OGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.35B | 917M | 1.02B | 864M | 187M |
| Depreciation & Amortization | 195M | 212M | 236M | 277M | 361M |
| Deferred Income Tax | (288M) | (18M) | (485M) | (160M) | 63M |
| Stock-Based Compensation | 59M | 75M | 101M | 105M | 77M |
| Change in Working Capital | 702M | (452M) | (155M) | (278M) | (247M) |
| Accounts Receivables | (277M) | (123M) | (212M) | 383M | 79M |
| Inventory | (138M) | (220M) | (230M) | (131M) | (13M) |
| Accounts Payables | 663M | (237M) | 163M | (157M) | (217M) |
| Other Working Capital | 454M | 128M | 124M | (373M) | (96M) |
| Other Non-Cash Items | 439M | 124M | 79M | 131M | 259M |
| Operating Cash Flow | 2.46B | 858M | 799M | 939M | 700M |
| Capital Expenditures | (488M) | (427M) | (261M) | (351M) | (162M) |
| Acquisitions (Net) | (185M) | (124M) | (2M) | (166M) | (198M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 192M | 131M | 1M | 4M | 0 |
| Investing Cash Flow | (481M) | (420M) | (260M) | (513M) | (390M) |
| Debt Repayment | 7.85B | (108M) | (258M) | (11M) | (458M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (17M) | (22M) | 0 |
| Dividends Paid | (145M) | (290M) | (294M) | (297M) | (88M) |
| Other Financing Activities | (9.03B) | (35M) | 0 | (38M) | (15M) |
| Financing Cash Flow | (1.33B) | (433M) | (569M) | (368M) | (561M) |
| Effect of Forex Changes | 23M | (36M) | 17M | (76M) | 150M |
| Net Change in Cash | 667M | (31M) | (13M) | (18M) | (101M) |
| Free Cash Flow | 1.97B | 431M | 538M | 588M | 538M |
Organon & Co.
NYSE:OGN
Intrinsic Alpha fair value
Locked
Current Price
$13.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.